PTSD

November 23rd 2024

During the COVID-19 pandemic, healthcare workers faced several mental health challenges, experiencing repeated exposure to life-threatening situations that increased their risk of PTSD and other trauma-related conditions.

November 20th 2024

After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.

August 12th 2024

In June, an FDA advisory committee voted against approval of midomafetamine capsules (MDMA) for adults living with posttraumatic stress disorder (PTSD).

June 5th 2024

Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.